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ABSTRACT 
BACKGROUND: HIV pre-exposure prophylaxis (PrEP) is a prescription antiretroviral 
medication that an HIV-negative person who is at high risk for HIV infection takes once per day 
to prevent infection. The most recent National HIV/AIDS Strategy identifies increasing PrEP 
uptake among men who have sex with men (MSM) as a pillar of ending the AIDS epidemic. Extant 
literature suggests that barriers to PrEP uptake among MSM are related to access, stigma, and 
knowledge/attitudes.  
METHODS: From February-March 2016, semi-structured interviews were conducted with 
researchers and practitioners in the HIV prevention field who work with MSM in Pittsburgh, 
Pennsylvania (n=11). An interview guide was used that asked about PrEP barriers and ways to 
mitigate these barriers. Interview recordings were transcribed and analyzed for key themes using 
ATLAS.ti software.  
RESULTS: The original list of 39 codes was condensed into five key themes. The five key themes 
are that PrEP is empowering; PrEP barriers are multidimensional and overlapping; episodic PrEP 
is viewed favorably; PrEP needs, access, and perceptions differ by race and age; and risk 
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compensation is real, but it should not be used to prohibit PrEP uptake. A list of all PrEP barriers 
identified in the interviews is presented. 
PUBLIC HEALTH SIGNIFICANCE: For public health practice, participants in these 
interviews identified stigma as more significant of a barrier to PrEP uptake for MSM than its 
discussion in the existing literature would suggest. PrEP enhancement efforts should 
simultaneously target multiple barriers across constructs for maximum effectiveness, avoid 
shaming overtones, and be inclusive of black MSM. A table is presented that may serve as a map 
to intervention design. Research is needed to test the association of PrEP use and STI incidence in 
US-based samples, to fine-tune local PrEP uptake efforts in other regions, and to monitor 
unintended consequences of PrEP uptake in the near or distant future. 
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1.0  INTRODUCTION 
The pandemic of HIV/AIDS persists around the world despite decades of prevention efforts from 
multifaceted local, regional, national, and international organizations. In the US, men who have 
sex with men (MSM) have been disproportionately burdened by the virus since the very beginning 
of the epidemic. While MSM comprise about 2% of the US population (1), they comprise 54% of 
people living with HIV/AIDS (2). Each year, 60-65% of total new infections are concentrated 
among MSM (2), and this number is higher among MSM in some regions of the country.  
Many interventions to diminish this disparity have taken a behavioral approach. 
Assessments of behavioral approaches to prevention intervention design illustrate the need for 
multifaceted approaches in the fight against HIV. Interventions to reduce HIV transmission among 
MSM have almost exclusively focused on outcomes such as risk behavior by modifying social 
factors at individual, group, and community levels (1-3). A meta-analytic review of 58 socio-
behavioral interventions concluded these approaches average a 27% reduction in risk behavior (2), 
and another concluded a 27% to 43% decrease in odds of risk behavior (3). The behavior change 
associated with behavioral interventions is often insufficient to decrease HIV incidence more than 
12 months post-intervention (4). While many of these interventions demonstrated efficacy, these 
findings evoke the need for additional prevention approaches. 
Socio-behavioral approaches may exacerbate the disparity in HIV infection by 
race/ethnicity among MSM. Socio-behavioral interventions are those that aim to reduce risk for 
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HIV transmission by measuring behavioral outcomes (e.g., condom use, condom negotiation, and 
number of sexual partners). The National HIV/AIDS Strategy calls for proportionally allocating 
resources based on epidemiologic need (5), and the heightened concentration of HIV incidence 
among Black MSM in the US is well documented. For example, Purcell et al. (6) conducted a 
meta-analytic review of seven nationally representative surveys in 2012 and estimated that HIV 
incidence among Black MSM was 6.0 times higher than White MSM, and 2.7 times higher among 
Latino MSM than White MSM. Furthermore, Millett et al. (7) concluded that Black MSM have 
three times the odds of testing HIV-positive compared with other MSM. One review of rigorously 
evaluated socio-behavioral interventions concluded that these interventions are more effective 
among White MSM than Black MSM (2). Findings that Black MSM do not have significantly 
different individual sexual behavior from other MSM (8) have forced others to conclude that we 
need to move beyond focusing on individual sexual behavior among Black MSM (9, 10).  
 A burgeoning body of evidence supports the augmentation of the socio-behavioral model 
with combination prevention approaches. Combination approaches incorporate behavioral, 
biomedical, and structural approaches (11) and target outcomes such as HIV testing and 
antiretroviral treatment for HIV-positive individuals (treatment as prevention, or TasP) (4). HIV 
pre-exposure prophylaxis, or PrEP, is a relatively new biomedical prevention method that is used 
in combination with condoms. PrEP is a prescription medication that an HIV-negative individual 
at increased risk of HIV infection takes daily to prevent infection (12). When used consistently 
and together with condoms, it has greatly reduced the risk of HIV transmission among diverse 
populations in several large-scale clinical trials (13-16). It is described in further detail in the next 
section. The White House’s National HIV/AIDS Strategy 2020, and HIV/AIDS campaigns in New 
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York state, San Francisco, Washington state, and Pittsburgh have identified expanding PrEP access 
as a key component to ending the HIV/AIDS epidemic (5, 17-19).  
 Many people who could benefit from PrEP are not connected to it. Gilead Sciences, Inc., 
the company that produces the only currently FDA-approved medication, reviewed records from 
about half of United States pharmacies that dispensed PrEP between January 1, 2012, and March 
31, 2014 (20). It found that just over 3,200 people had started the PrEP regimen during that period 
(20). Meanwhile, the Centers for Disease Control and Prevention (CDC) estimate that 500,000 
Americans could benefit from PrEP, including one in four MSM (20, 21). Other researchers have 
identified reasons for low uptake such as the drug’s high cost (22-26), stigma in the community 
(22, 27-29), and lack of awareness among providers and patients about the medication’s potential 
for preventing HIV (29-37).  
 This thesis explored barriers and facilitators to PrEP uptake by interviewing employees of 
HIV-prevention organizations who work with the MSM community in Pittsburgh, Pennsylvania. 
This project aimed to gather data regarding barriers and facilitators of PrEP uptake, which may be 
used to inform public health practitioners, researchers, advocates, and policy-makers to better 
understand how MSM can be connected to PrEP more effectively. First, background information 
about HIV prevention efforts, about PrEP itself, and conceptual frameworks relevant to the 
research purpose are presented. Then, a description of the study’s methods are described in detail, 
followed by a presentation of interview results. After that, the results are discussed and 
consolidated with conceptual frameworks to present implications of these findings for future 
public health research and practice.  
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2.0  BACKGROUND 
2.1 OVERVIEW OF HIV PREVENTION EFFORTS 
This section begins by setting the context for HIV pre-exposure prophylaxis, or PrEP, by 
presenting a brief overview of HIV prevention efforts in the US. Condom use is the first known 
HIV prevention method, with the first publications to advocate for condom use to protect against 
HIV infection being traced to San Francisco in 1982 (38). By the mid-1980s, hundreds of 
community organizations had formed to care for individuals dying of AIDS and to advocate for 
more action from politicians, scientists, and doctors (38). In 1987 the World Health Organization 
established the Special Programme on AIDS (later the Global Programme on AIDS), which widely 
promoted condom promotion, sex education in schools, simplified treatment of other STIs, syringe 
exchange programs, and efforts to improve safety of the blood supply (38). Today, other 
prevention methods include reductions in sexual or needle-sharing partners, male circumcision, 
and treatment with antiretroviral medications (or PrEP) (11). The future of HIV prevention “must 
draw from the successes of existing evidence-based interventions and the expertise of the market 
sector to integrate preventive innovations and behaviors into everyday routines” (11). 
2.2 WHAT IS PREP? 
Pre-exposure prophylaxis, or PrEP, is the use of an antiretroviral medication to prevent HIV 
infection in HIV-negative individuals. PrEP must be prescribed by a medical provider. Currently, 
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the only medication that is FDA-approved for use as PrEP is Truvada®. It is a single tablet that 
contains emtricitabine and tenofovir disoproxil fumarate (FTC-TDF) (13). If an HIV-negative 
individual is exposed to HIV but has sufficient levels of FTC-TDF in the bloodstream, genital 
tract, and rectum, the virus is prevented from entering cells and replicating, and the individual 
remains uninfected (13). It must be taken every day for maximum protection (13), and intracellular 
levels of FTC-TDF in rectal tissue and blood that are sufficient for protection occur after seven 
daily doses (39). In vaginal and cervical tissue, this may take up to three weeks (39). Some have 
called for alternatives to the daily regimen, known as episodic PrEP, because of observations that 
protection is only necessary during high risk episodes (40).  
2.3 EFFICACY OF PREP FOR THE PREVENTION OF HIV INFECTION 
Clinical trials have found that PrEP is highly efficacious among people who adhere to its treatment 
regimen. The iPrEx trial (13) enrolled 1,251 MSM in its PrEP treatment arm, and those who took 
the drug every day reduced risk of HIV infection by 99% (adherence was confirmed via blood 
analysis). Those who took it four days per week had a 96% reduction in risk (13). However, eight 
weeks into the trial, 45% of treatment arm participants had no detectable FTC-TDF in blood 
analysis (41). This indicates that adherence was a sizable issue.  
A less demanding PrEP treatment regimen has demonstrated efficacy for preventing HIV 
infection, known as episodic PrEP. The IPERGAY trial (40) prescribed episodic PrEP, also known 
as event-driven or on-demand PrEP, to HIV-negative MSM who reported unprotected anal sex 
(n=199), and they found an 86% relative reduction in HIV infection compared to placebo control 
(n=201). The trial’s participants were instructed to take two tablets of FTC-TDF or placebo two to 
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24 hours before sex, then another tablet 24 hours later and a fourth tablet 48 hours later (40). 
Participants used a median of 14 tablets per month (40). 
2.4 IMPLICATIONS OF PREP TO COMBINATION PREVENTION 
PrEP is an efficacious bio-behavioral intervention that fills a unique niche in HIV prevention (42). 
It may be a viable prevention method for MSM who do not use condoms. In a recent sample of 
HIV-negative Black and Latino MSM in three US cities who were recruited through online, 
agency, and street/venue outreach efforts (n=605), and were not already taking PrEP, Mansergh et 
al. (43) found that 52% of the men had anal sex without a condom in the prior three months. 
Respondents who reported recent sexual risk behavior were more likely than those who did not to 
prefer PrEP compared with condoms (43).  
2.5 CONCEPTUAL FRAMEWORKS 
The methods and analysis in this study were guided by theories and models from the fields of 
public health, health disparities, and psychology. Applicable frameworks were identified through 
a review of peer-reviewed literature about interventions that focus on medication use and 
adherence, behavior change, and HIV risk behavior. Frameworks that have been used to inform 
discussions of medication use include the Theory of Planned Behavior in hypertensive patients 
(44), the Health Belief Model in hypertensive patients (45) and HIV-positive patients (46), and the 
Transtheoretical Model in HIV-positive patients (47, 48). The Theory of Planned Behavior, which 
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has also been used to study gay affirmative behavior (49), posits social pressures and norms as 
influences to goal-oriented behavior (50). The Theory of Syndemic Production suggests that social 
marginalization experienced by MSM may manifest in a fear to access health services (51). 
Because PrEP uptake relies on an interplay of factors at multiple levels of society, the Social 
Ecological Model (52) was also examined.  
 These frameworks are instrumental in identifying strategies to connect high-risk MSM to 
PrEP more effectively. With contextual information about organizational and community strengths 
and needs derived from interview sessions, examination of existing frameworks will inform 
recommendations for actions that can be taken by HIV practitioners, researchers, advocates, and 
policymakers to mitigate barriers to PrEP uptake among MSM.  
2.5.1 HEALTH BELIEF MODEL 
The Health Belief Model (HBM) delineates a framework for understanding why an individual 
engages, or does not engage, in behaviors that are beneficial to his health (53). A researcher using 
the HBM analyzes the association of a given behavior to perceived susceptibility to and perceived 
severity of disease, perceived benefits of and perceived barriers to behavior change, cues to action, 
and self-efficacy (53). Practitioners apply the model’s key constructs to develop effective 
interventions that target health behavior through education about risks, for example (54). 
HBM’s constructs have previously been applied in the context of HIV-protective behavior 
such as condom use and HIV testing and counseling. Zhao et al. (55) analyzed data from female 
sex workers and found that perceived benefits and perceived barriers were proximate predictors of 
condom use (r=0.23 and r=-0.62, respectively), and that self-efficacy had a direct effect on 
perceived severity, perceived benefits, and perceived barriers, which was indirectly associated 
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with condom use (r=0.36). Nöthling and Kagee (56) found that perceived severity of HIV and 
perceived benefits of and barriers to HIV counseling and testing explained 25.1% of the variances 
in acceptance of counseling and testing among South African university students. To this author’s 
knowledge, there is currently no research in the peer-reviewed literature that explores HBM 
constructs among MSM with PrEP uptake as the outcome variable.  
2.5.2 SOCIAL ECOLOGICAL PERSPECTIVE 
The interplay of personal and environmental factors needs to be considered. The Social Ecological 
(SE) perspective encourages the examination of factors at five hierarchical levels of individual, 
interpersonal, community, organizational, and policy (52). Policies that make PrEP accessible, 
mechanisms that make it known among communities, social norms that make it acceptable, 
interpersonal interactions with healthcare providers that are productive and with sexual partners 
who are supportive, and individual factors that support medication adherence all must coalesce. 
At the individual level, adherence to the PrEP regimen requires a change in behavior, since it 
requires taking a tablet every day. At the interpersonal level, PrEP enrollment requires a patient 
who is MSM to disclose sensitive information about gay/bisexual identity and behavior to a 
healthcare provider. At the community level, social norms may inhibit PrEP uptake and adherence 
due to stigma (22, 27).  
On the organizational and policy levels, accessibility can be increased through 
organizational and governmental policies that reduce its cost and increase its acceptability. 
Medicaid plans in some states cover prescription costs for PrEP, and some states have created 
programs to cover pre-prescription laboratory testing. Additionally, findings from the IPERGAY 
trial may have implications on the cost of a PrEP prescription. The FDA approved the use of PrEP 
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with a daily regimen for which the iPrEx trial found strong efficacy (13). However, the IPERGAY 
trial found efficacy for PrEP with a regimen that prescribes use only during high-risk periods (40). 
This may be a less costly alternative because fewer tablets are needed; participants in that trial 
used a median of 14 tablets per month (40). Elsesser et al. (57) found that 74.3% of MSM in a 
large web-based sample (n=7503) considered a short-term PrEP regimen during high-risk periods 
to be acceptable, and MSM who engaged in unprotected anal sex while on vacation in the past 
year were more likely to indicate interest than respondents who did not. Thus, the reasons that the 
FDA may consider approval of this regimen are twofold: it is less costly and it is easier to adhere 
to. 
2.5.3 THEORY OF SYNDEMIC PRODUCTION 
MSM who meet the criteria for PrEP eligibility may be experiencing psychosocial health issues 
that need to be considered. Stall et al. (58) found that psychosocial health problems including 
clinical depression, substance abuse, partner violence, and childhood sexual abuse are highly 
interconnected for MSM living in urban environments and that greater numbers of health problems 
are positively associated with high-risk sexual behavior. Stall, Friedman, and Catania (51) suggest 
that while not all MSM experience multiple, or any, of these outcomes, the ones who do may be 
less likely to seek health services. The Theory of Syndemic Production connects the presence of 
these health disparities among MSM to experiences of marginalization and stigma associated with 
gay/bisexual affiliation across the life course (51, 58).  
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2.5.4 TRANSTHEORETICAL MODEL 
The Transtheoretical Model (TTM) proposes five stages of behavior change that individuals 
experience when changing health behavior (59). Intervention design may be targeted to individuals 
in a given stage to modify health behavior, with the goal of helping the individual move through 
the model’s stages and lead to sustained behavior change (59). The five stages are 
precontemplation, contemplation, preparation, action, and maintenance (59). During 
precontemplation, an individual has no intention to take action, and in contemplation, the 
individual intends to take action within six months (60). An individual is in the preparation stage 
when he intends to take action within 30 days and has already taken some steps to do so, and the 
action stage is when overt behavior change has occurred within six months (60). The final stage, 
maintenance, signifies that the behavior change has been sustained for at least six months (60). 
Ficke and Farris (61) found that from 1995 to 2004, eleven articles in the peer-reviewed 
literature applied TTM to medication use. Genberg et al. (48) applied TTM to antiretroviral 
adherence among HIV-positive patients in the New England area. Among the patients in this 
sample (n=137), those in the action and maintenance stages of change were significantly more 
likely to adhere to their medication than were the patients in the precontemplation, contemplation, 
or preparation stages (48). Therefore, the two end stages of the model are ideal; however, an 
individual most commonly proceeds through the first three to get to that point (60). Public health 
practitioners who aim to increase PrEP uptake among high-risk MSM might consider including 
stages of change indicators in needs assessments, goal-setting, intervention design, or outcome 
evaluations.   
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2.5.5 THEORY OF PLANNED BEHAVIOR 
Originally developed by psychologists to predict goal attainment among college students, the 
Theory of Planned Behavior (TPB) considers the associations of attitude, perceived behavioral 
control, and subjective norms to behavior change intentions and execution (50). Subjective norms 
in the model are measured by normative beliefs about social pressures. Ho and Lee (44) adapted 
TPB to study medication adherence in hypertensive patients. They found a positive correlation of 
attitude, perceived behavioral control, and subjective norms with intent to adhere to medication 
(r=0.27, p=0.00), and a positive correlation of intent with actual medication adherence (r=0.49, 
p=0.00) (44). Andrew, Mullan, and de Wit (62) conducted a meta-analysis of peer-reviewed 
literature that examined the corrleates between TPB constructs and condom use among MSM. 
They found that attitude, subjective norm, and perceived behavioral control significantly correlated 
positively with condom use intention, which in turn accounted for 12.4% of the variance in condom 
use behavior (62). Interventions to increase PrEP uptake may consider measuring the intent to use 
PrEP and targeting attitudes and group-level social pressures about PrEP. 
2.6 EXISTING BARRIERS AND FACILITATORS TO PREP UPTAKE 
With an understanding of how theory informs approaches to increasing PrEP uptake, a review of 
barriers to PrEP uptake was conducted in peer-reviewed empirical literature. The three barriers of 
no access, lack of knowledge, and stigma were identified. Additionally, a scan was conducted of 
existing practices at the organizational or policy level that may mitigate these barriers. These 
strengths and needs were considered in construction of the interview guide used in this research.  
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Low access to PrEP is a significant barrier for many who would benefit most, with cost 
and connections to providers who will prescribe being important factors (22-26). The White 
House’s National HIV/AIDS Strategy documents the correlation between high poverty rates and 
high risk of HIV infection (5). Truvada’s manufacturer, Gilead Sciences, Inc., provides assistance 
for uninsured populations and co-pays for those who are insured (enrollment forms available at 
https://start.truvada.com/paying-for-truvada). The Partnership for Prescription Assistance 
program helps uninsured populations access prescription medications at low to no cost 
(https://www.pparx.org). Medicaid coverage leverages public assistance for uninsured populations 
to access a PrEP prescription. For people who are insured, the Patient Access Network Foundation 
will cover co-pays for any prescription medication, and for PrEP, grants may be up to $7,500 per 
year (http://panfoundation.org/hiv-treatment-and-prevention).  None of these options cover 
provider visits and laboratory testing that are required for a PrEP prescription, but some states have 
created additional programs to cover these costs. 
Low knowledge of PrEP in both the medical community and MSM communities may also 
be a barrier. The CDC (21) reported that one in three primary care providers in the US has not 
heard of PrEP. Among MSM, the numbers may be even lower. Less than 20% of MSM in a sample 
from Pittsburgh have heard of PrEP (63). However, more recent evidence elsewhere may indicate 
this is changing. Hood et al. (64) found that 86% of HIV-negative men who reported high-risk 
sexual behavior in a survey at the 2015 Seattle Gay Pride Parade (n=2168) were aware of PrEP, 
up from 13% in 2012. The New York City Department of Health and Mental Hygiene (DOHMH) 
is executing a PrEP education campaign with dual provider and community arms. While this 
initiative has yet to be evaluated, the campaign is similar to a DOHMH condom campaign from 
2007 to 2008 that was considered to be highly effective (65). 
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Stigma related to PrEP as an HIV-prevention treatment for high-risk populations has also 
been identified as a barrier. Knight et al. (27) conducted 50 interviews with young men in 
Vancouver and some of the gay men in the sample expressed views that given its eligibility criteria, 
PrEP enrollment serves as a signal for one’s stigmatized status as sexually promiscuous. Mack et 
al. (29) identified community-level stigma to be the most significant barrier to PrEP enrollment 
for MSM, through 20 interviews with HIV prevention experts in Kenya. Community-level stigma 
may be exacerbated due to conflicting views within the HIV prevention community itself. Some 
have denounced PrEP due to the perception that rates of sexually transmitted infections (STIs) will 
increase due to risk compensation (22). However, in a sample of 544 HIV-negative MSM in 13 
sexual health clinics in England, McCormack et al. (28) detected no difference in STI incidence 
between treatment and control. 
2.7 HIV IN PITTSBURGH, PENNSYLVANIA 
The American Community Survey (66) estimated that the population in Pittsburgh, Pennsylvania, 
is 306,045, with a density of 5,521 people per square mile. Pittsburgh is the largest population 
center of Allegheny County, which has a population of 1,229,172 people and population density 
of 1,676 people per square mile (66).  
 The HIV epidemic in Allegheny County, Pennsylvania, has remained consistent over the 
past 12 years (67). Neither the prevalence nor incidence of HIV in the general population has 
shown a noticeable decline since 2004, and men are disproportionately impacted by the virus (68). 
In 2013, the most recent year for which county data are reported, the incidence of HIV was 20 per 
100,000 males and 3.6 per 100,000 females (68). There were 1,948 total known cases as of the end 
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of that year, and 1,584 (81.3%) of those individuals were male (68). As is the case nationwide 
(69), sex with men continues to be the largest driver of HIV transmission among men in Allegheny 
County, accounting for 87% of transmission among men (68). Nationwide, 60-65% of new yearly 
HIV infections were among MSM in recent years (69), but in Allegheny County this proportion 
was 86% in 2013 (68). 
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3.0  METHODS 
3.1 PARTICIPANT RECRUITMENT AND SAMPLING FRAME 
This paper presents data collected through interviews conducted with experts who work with 
HIV/AIDS issues and MSM populations in Pittsburgh, Pennsylvania. Pittsburgh was chosen 
because its yearly HIV incidence has not significantly decreased over the last decade (9), MSM in 
Pittsburgh have low knowledge and uptake of PrEP compared to other cities (10), and Pittsburgh 
is a mid-sized city that is a hub of HIV/AIDS research and practice. Purposive sampling was 
employed to achieve a sample with maximum variation. Maximum variation is desirable in 
qualitative research when expertise is sought from different people with different backgrounds 
who work in different settings (70, 71).  
 An environmental scan of organizations in Pittsburgh that work in HIV prevention was 
conducted to compose a recruitment list. The scan identified 11 organizations including clinics, 
academia, nonprofits, a local health department, and one foundation. Leaders from each 
organization were contacted via email to be interviewed. See Appendix A for the recruitment email 
that was used. In some cases, the initial contact agreed to interview, and in others, he or she referred 
to one of his or her co-workers. During one interview session, a participant recommended three 
individuals who were later contacted and interviewed. In total, 18 individuals from 10 
organizations were contacted, and this yielded a final sample of 11 participants from seven 
organizations across nine interview sessions. 
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3.2 INTERVIEW GUIDE DEVELOPMENT 
An open-ended interview guide was developed prior to interview facilitation. The guide was 
designed to inspire discussion with participants without dictating content. The interview questions 
were about the participant’s organization and the community with which he or she works, not 
about the participant individually. The guide was modified before each interview to reflect 
differences in the participant’s organization. Questions were categorized by organizational 
characteristics, barriers to PrEP uptake (stigma, knowledge, cost), and inter- and intra-
organizational strengths. If needed, the structure was modified ad hoc during each interview 
session depending on the natural flow of conversation. 
The interview guide was reviewed by advisors in the University of Pittsburgh Center for 
LGBT Health Research before implementation to ensure coherence and comprehensiveness. The 
interview guide appears in Appendix B. Upon consultation with the University of Pittsburgh 
Institutional Review Board (IRB), it was determined that this study did not constitute Human 
Subjects Research, and therefore the study protocol did not require IRB submission or approval. 
3.3 DATA COLLECTION 
Nine semi-structured interviews were conducted by this author during February-March 2016 with 
11 participants in Pittsburgh, Pennsylvania. Eight of the interviews were with a single participant, 
and one interview included three participants at once. Most interviews occurred at the participants’ 
workplaces, and one interview took place at the University of Pittsburgh, Graduate School of 
Public Health. Each interview took place in a quiet location to ensure clarity for the audio 
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recording. The highest degrees held by participants are MPH (n=3), MSW (n=3), MD (n=2), MSN 
(n=1), MBA (n=1), Certified Registered Nurse Practitioner (n=1), BA (n=1), and a high school 
diploma (n=1) (some participants have more than one degree). See Table 1 for the participants’ 
job roles. The audio recordings were transcribed clean verbatim by a professional transcription 
service, and transcripts were checked for accuracy by this author with the corresponding audio 
recordings. Interviews were between 30 to 65 minutes in length. Notes were made immediately 
following each interview session to summarize important points and record any data that might 
have not been captured in the audio recording (for example, information from tours of the physical 
space before or after the interview session). 
Table 1. Participant Job Roles. 
Participant Role 
P1 Academic researcher; PCP 
P2 Program Director 
P3 Research Specialist 
P4 Program Specialist 
P5 Project Manager 
P6 Program Director 
P7 Program Specialist 
P8 Program Specialist 
P9 Program Director; PCP 
P10 Program Director 
P11 Public Health Official 
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3.4 ANALYSIS 
Content analysis as described by Patton (70) was performed on interview transcripts. Common 
themes were coded and illustrative quotes were identified. Thirty nine primary codes were 
identified in an initial open coding process on the first six interview transcripts (eight participants 
total), and these were condensed into five key themes. Data management and analysis were assisted 
by the use of ATLAS.ti software. 
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4.0  RESULTS 
The open coding process yielded 39 codes, and five key themes emerged from these. See Table 2 
for a summary of results. The results and illustrative quotes from this table are expanded upon in 
the proceeding section. 
 
Table 2. Key Themes from the Interviews. 
Key Themes Illustrative Quotes 
PrEP is empowering. I've heard a lot of really, really positive talk around, "Wow, you're on PrEP. You're doing the things you need to do to take care of yourself and other people.” 
PrEP barriers are 
multidimensional and 
overlapping. 
How do you pay for [PrEP]? Do you have culturally competent services? Do you 
have bus access to get there? Do you trust the pharmaceutical company in the 
first place that they're not going to be messing with you and have side effects 
down the line? So a lot of that I think factor[s] in. 
Episodic PrEP is 
viewed favorably. 
If you're at a risky time in your life… you can take PrEP for six months and stop 
taking PrEP… It's not something that you have to take for the rest of your life… 
It's not forever. 
PrEP needs, access 
and perceptions differ 
by race and age among 
MSM. 
The “Truvada Whore” conversation is more for middle-age, work-force men. I 
think that younger people are not calling each other “Truvada Whores.” I think 
that especially in the African-American community, the chances [of HIV 
infection] are really high. So it's not as much of a joke. 
Risk compensation is 
real, but it should not 
be used to prohibit 
PrEP uptake. 
We saw [STI] increases go up way before PrEP. I don't believe that PrEP 
actually was part of it. I think it could potentially contribute to that, but I don't 
think it was the initial spark for driving it here in the first place. 
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4.1 PREP IS EMPOWERING. 
Participants noted that PrEP empowers MSM in various ways. PrEP was described as empowering 
because many MSM take PrEP to feel like they are taking care of themselves and/or taking care 
of sexual partners; it is an opportunity for MSM to advocate for their own health to their providers; 
and it mitigates fear associated with sex that many MSM have experienced since the onset of the 
HIV/AIDS epidemic. The view emerged of PrEP as a harm reduction approach that contrasts 
“paternalistic” (Participant 1) approaches to care (to be discussed in a later section). 
 Several participants explicitly discussed PrEP as a method for individuals to take care of 
themselves or others. Participant 7 (P7) said that her clients, who are predominantly young Black 
MSM and Black trans women, have “really positive talk around, ‘Wow, you’re on PrEP. You’re 
taking care of yourself.’” Additionally, given that PrEP enrollment requires a patient to visit a 
medical setting for testing every three months, P1 pointed out that it keeps individuals engaged in 
healthcare. P1, a physician who cares for MSM in a PrEP-prescribing medical clinic, said that for 
this reason many STIs are caught early and treated. P1 also discussed the theme of empowerment 
in the context of serodiscordant relationships and PrEP: 
I think the reason why a negative partner might consider going on PrEP is that this 
is something that he or she can do to protect himself or herself, as opposed to 
depending on somebody else to maintain undetectable viral load, because we know 
that while communication should be ideal and should be open ended - things 
happen. This is something someone can do for himself or herself if he's in a 
serodiscordant relationship, to protect (P1). 
 
Other participants offered an empowerment view from a structural standpoint: 
You can't control what people do. I'm a big proponent of harm reduction. I think 
you have to give people the tools to make informed decisions and keep themselves 
safe. At the end of the day, it's up to them. And I think there's that, when you're 
talking about public health, there's the individual decision-making and risk factors, 
but I think where we as public health people, as community collaboratives, as 
healthcare systems, we need to be focusing on environmental change, making the 
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environment in which individuals live more conducive to healthy decision-making 
(P5). 
 
The view of PrEP as a harm reduction approach to HIV prevention emerged in the interviews. 
While this view is not unique to this sample, several participants expressed positive views about 
PrEP because it allows them to “meet the client where they are” (P4). On the harm reduction 
perspective and PrEP, P11 said: 
PrEP is really, in my mind, a harm reduction approach. In the sense that as a 
healthcare provider, or someone who works with people who are sick or need to 
have some change in their life, telling people that they should change is 
really ineffective. I've never had anybody who stopped using drugs or having 
unprotected sex because I told them it was a good idea, it always takes more than 
that. It's more of a process and our job as healthcare providers is to keep the people 
as healthy as we can until they get to the place where they want to be (P11). 
 
 Several other participants described how PrEP is empowering because it may equip their 
clients and patients with the language to advocate for themselves in a healthcare setting. One 
participant who is a counselor described how PrEP has enhanced his provider-client relationship 
and his clients’ own health literacy: 
I don't mind going and maybe advocating for that person. Or, I would ask them 
like, "Well, what type of information are you looking from your doctor?" I may be 
able to provide that information [to] them, or I may be able to develop strong 
questions so that they can go back to their provider that they're used to and ask 
those questions and advocate for PrEP on their own (P8). 
 
 Several participants discussed how PrEP mitigates the fear that many MSM felt during 
“the early cases of HIV in like 1980” (P9), which was described as an empowering feeling. As 
one participant said: 
So I think people have lived under this cloud of fear around their sex and their 
sexuality for a long time, and to be able to lift that a little bit for people I think is 
not what PrEP was intended to do, but if it makes people feel better and safer about 
having sex then I think that's good prevention and it's just good healthcare (P9).  
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4.2 PREP BARRIERS ARE MULTIDIMENSIONAL AND OVERLAPPING. 
Participants identified various types of barriers to PrEP uptake for MSM. The identified barriers 
are multidimensional because they can be organized into constructs, and they are overlapping 
because some barriers may feasibly be categorized into more than one construct. All identified 
barriers are listed in Table 3, and they are expanded upon below. This list is intended to be 
extensive but not exhaustive. All of the barriers identified by participants in this sample were 
placed into three constructs of Access, Stigma, and Knowledge/Attitudes.  
 
Table 3. List of Barriers to PrEP Uptake Identified in the Interviews. 
Access Stigma Knowledge/Attitudes 
• High cost 
• Lack of insurance 
• Co-pays above Gilead 
assistance allotment 
• Lack of connections to 
PrEP-prescribing providers 
• Insufficient capacity 
among organizations   
• Image of the “Truvada 
Whore”  
• Image of PrEP as a 
“party drug” (i.e., 
assumptions about risk 
compensation) 
• Discussions about sex 
and sexuality are often 
difficult 
• Internalized homophobia 
and self-shame 
• Fear of side effects 
• Lack of awareness in 
community members and 
medical providers about what 
PrEP is and how to get it 
• Inaccurate self-assessment of 
HIV risk by community 
members 
• Fatalistic attitudes 
• Distrust of medicine/big 
pharma 
 
4.2.1 ACCESS-RELATED BARRIERS 
Access to PrEP was a primary barrier to uptake that was identified in the interviews. These barriers 
included PrEP’s high cost, insurance issues, and lack of connections to PrEP-prescribing providers. 
As P5 noted, just because PrEP is legal and FDA-approved, the reality for MSM “on the ground” 
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is more complicated. To elaborate, P5 offered specific examples of access-related barriers that 
were also echoed by others in the sample: 
How do you pay for it? Do you have culturally competent services? Do you have 
bus access to get there? Do you trust the pharmaceutical company in the first place 
that they're not going to be messing with you and have side effects down the line? 
So a lot of that I think factor in terms of justice [sic] (P5). 
 
 P5’s examples are not an exhaustive list of access-related barriers, but cost and access to a 
provider/clinic were the two access-related barriers most often discussed by the sample. 
Participants said that many people do not have a regular provider or they do not feel like they can 
talk about PrEP with their provider, which may be due to lack of ability to self-advocate in the 
healthcare setting and/or fear of discrimination. On the provider side, P1 noted that PCPs may not 
feel comfortable bringing up the topic or that they do not have enough time during appointments, 
because “sex is not a three-minute conversation.”  Organizational barriers were described as 
capacity issues in accommodating PrEP’s clinical guidelines, including but not limited to 
comprehensive blood testing pre-prescription and every three months thereafter, and “red tape” 
(P10) that is associated with having a provider who can prescribe PrEP on-site. 
 Insurance issues came up in several of the interviews. Many participants discussed payment 
assistance plans for uninsured and underinsured populations, and it was discussed that some plans 
have paperwork that may be difficult for the layperson to navigate. For example, Gilead’s payment 
assistance plan was identified by P8 as being easier to enroll in than dealing with Medicaid. 
Additionally, participants noted that they see cost-prohibitive issues commonly among people who 
are on basic insurance. As noted by P3: 
I think it's interesting that it's easier to be on PrEP if you're uninsured than it is if 
you are insured. Unless you have good insurance that covers the majority of your 
out-of-pocket costs, it's still pretty tough to obtain PrEP. The copay assistance I 
think only pays about thirty six hundred a year, which is three hundred a month. 
And so if your co-pay is more than that, then you're out of luck (P3). 
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Furthermore, P3 noted that many of his clients who are under 26 and on their parents’ health 
insurance plan are concerned that their parents will know if they enroll in PrEP.  
4.2.2 STIGMA-RELATED BARRIERS 
Stigma-related barriers emerged in several forms during the interviews. Stigma against PrEP itself, 
status as MSM or gay/bisexual, and sex in general were identified during the interviews. Some 
barriers were on the individual level and some were on the community level. 
 A prominent stigma-related barrier that was discussed was the perception of PrEP as a 
“party drug.” This term always carried a negative connotation in the interviews, and it was used 
differently among the participants. On an individual level, P9 noted that asking about PrEP may 
be seen as a signal for being sexually promiscuous, and that some MSM fear that label. P9 
discussed how some MSM may hesitate asking a PCP in the privacy of a medical visit out of fear 
of judgment from the provider. However, P8 noted that he did not notice this fear among his clients, 
who are predominantly young Black MSM and Black transwomen: “From what I gathered we 
don't have the whole stigma around, like if you are on PrEP that you're going to go sleep with 
everyone and everything.”  
 Additionally, the “party drug” stigma had a community-level dimension. Some MSM may 
forego a PrEP prescription due to the vocalization of “anti-PrEP” views among their peers. One 
example of “anti-PrEP” views was described by participants as the fear that PrEP is going to cause 
“this feeding frenzy of crazy, condomless sex” (P1), and in turn increase other STIs and drug-
resistant HIV. Notably, P1 pointed out that among his patients who are having unprotected sex 
while on PrEP, most of them were not avidly using condoms before going on PrEP, and also, that 
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increases in STI rates nationwide began before PrEP was approved by the FDA. P11 speculated 
on other causes of upticks in STI incidence: 
The normalization of anonymous and multiple sex partners that I think is rampant 
right now through social media [sic]. The Tindr’s and Grindr’s and all the other 
online hookup apps I think are having a quite an impact on STD risk-taking 
behavior. The idea that you can GPS a sexual partner just like you can GPS a taxi 
(P11). 
 
Additionally, a second “anti-PrEP” view discussed by a participant was the fear among HIV-
positive MSM that insurance premiums will increase for HIV medications. However, the 
participant went on to say this about these “anti-PrEP” views: 
I could analyze it as being weird like jealousy of why wasn't this around - why didn't 
people think about this before we contracted the virus? (P2). 
 
 Stigma about sex in general was also cited by participants. P10 explained that some MSM 
are apprehensive about going on PrEP because “there is that stigma of sex-shaming” (P10), and 
PrEP requires frank conversations about sex. He later expanded on his point: 
[They] may be embarrassed to ask about it, because they've heard that only sluts 
take it, or they don't ask about it because - talking about sex in general, we're a 
very Puritanical society when it comes to that, which is so weird when our movies 
and TV - we have a very wonderfully slutty pop culture. It's really built around sex, 
drugs, and rock 'n roll. But you sit down at the dinner table and all of a sudden we 
are like the Puritans. You don't want to talk about sex. Nobody wants to talk about 
it because it's embarrassing (P10). 
 
 Fear of discrimination from a provider was cited as a stigma-related barrier by P3, who 
pointed out that asking about PrEP requires a discussion about sexual behavior, and not all MSM 
want to “out themselves” to their PCP. Input from a health department official (P11) may mitigate 
this barrier, particularly on his views about how the local health department fills a demand for 
sexual health services that are anonymous and neutral: 
I see the health department not only as a traditional care provider, but also because 
of it's kind of neutrality and anonymity in a way [sic], I think we are - I know we do 
provide a service to not only the broad community, but for those who again, fall 
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through the cracks. Who don't feel comfortable going to your traditional care 
model, they don't want to go to the Ivory Towers and ride the elevator up past 
inpatient units and be part of this whole big medical infrastructure. They like the 
idea of this relatively neutral kind of confidential site (P11). 
4.2.3 KNOWLEDGE/ATTITUDE-RELATED BARRIERS 
Knowledge- and attitude-related barriers included the lack of awareness of what PrEP is and how 
to get it, inaccurate self-assessment of HIV risk, fear of side effects, “fatalistic attitudes,” and 
medical distrust.  
 The lack of awareness about PrEP was discussed as a problem among both patients and 
PCPs. Some participants articulated that many MSM who know what PrEP is do not know where 
or how to get a prescription, particularly among those who do not have a PCP, do not want to talk 
about PrEP with their PCP, or see a PCP who does not know about PrEP. Several participants 
noted that lack of knowledge about PrEP among providers (e.g., treatment regimen, eligibility 
criteria, billing codes) is an issue:  
Knowing where to get PrEP [is an issue], I think a lot of people have had trouble 
actually finding providers, and so when people call [around the city] they usually 
get referred to me… [it] is like, "How do I talk to someone about PrEP?" I think 
this person was trying to get in touch with me and they called my clinic. And we're 
like, "We can't call you. We can't have the doctor call you because he's never seen 
you before." So then what do you do? Like, if they have a question about this, that, 
and the next thing. So people are kind of like stuck in that particular situation (P1). 
 
 Participants recognized that even among their patients and clients who know what PrEP is, 
they may decide to not seek a prescription because they are self-assessing their risk incorrectly: 
They think that they're not at risk. And it could be true for some. Not every 
individual who comes [here] is sexually active… But it's interesting that we have a 
lot of people who just don't consider themselves at risk for HIV (P7). 
 
 Many participants described a fear of side effects and a fear of interaction with alcohol and 
other drugs as prevalent barriers among the MSM that they work with. Participants said many of 
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their clients and patients believe that PrEP will come with burdensome side effects, because it is a 
medication for HIV: 
Most question I get [sic], "Is it going to affect my body?" "What are the side 
effects?" "Does it hurt my lungs?" "Does it hurt my liver?" I think I've heard every 
organ. "Does it hurt my heart?" So they have these questions because they know 
that in the past HIV medicines have side effects and they do affect your body long-
term (P8). 
 
Many participants agreed that the most at-risk MSM are not being connected to PrEP, and 
several discussed the prevalence of “fatalistic attitudes” in this context: 
[When] thinking about populations that may be vulnerable to a number of 
structural justice factors - if someone is housing insecure, if they don't have food, 
if they don't have a safe place to be during the day... those are the things that you 
need to take care of first and PrEP is probably lower down on the list… so if you're 
just in survival mode day-by-day, PrEP might not be on the radar… I am hearing 
a lot about people who have fatalistic attitudes, in terms of, "I'm going to get [HIV] 
anyway," or if they do become HIV-positive, they're not surprised (P5). 
 
Several participants noted that their patients and clients who are informed about PrEP are 
usually informed about health-related issues in general, and participants expressed uncertainty 
about how to reach those who are not: 
I think that we have a subpopulation that is informed about PrEP, just as we have 
a subset of our population who is informed about HIV and regularly gets tested. 
But the question then becomes what percentage is that subset, and how do we reach 
everyone else with that same information? (P8). 
 
 Distrust of medical and pharmaceutical actors was identified as another barrier related to 
knowledge/attitudes, for two different subpopulations of MSM. P6 identified that many of her 
clients have a “larger distrust of the medical system,” who are predominantly young Black MSM 
and Black transwomen. P4, who works primarily with injection drug users of all races, pointed out 
that many of her patients avoid medical settings in general, because they do not want to undergo 
blood testing that may show traces of illicit substances and be recorded on their medical records. 
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4.3 EPISODIC PREP IS VIEWED FAVORABLY. 
Participants supported episodic PrEP and said that the communities that they work with view it 
favorably. It was often described in the context of harm reduction. However, many noted that 
episodic PrEP is not well known among their clients or patients, with P2 saying “that message has 
not been delivered very well to people in the community” and that many MSM only know of PrEP 
as a pill that you have to take every day. Participants who see patients or clients said that they 
speak with their patients about using PrEP during high risk periods of their lives. P8 said that he 
often emphasizes that it is not a lifetime commitment in client conversations:  
If you're at a risky time in your life, if you're participating in sex work or if you're 
at a point where you're in college and you're not in a relationship and you are 
having lots of sex, you can take PrEP for six months and stop taking PrEP, and 
then get back on PrEP if you need to… It's not something that you have to take for 
the rest of your life. And that's what I've been telling people... People know you 
have to take HIV meds for the rest of your life. So they're thinking, “Oh PrEP, that's 
one pill a day forever.” No, it's not forever. You can utilize it during a high risk 
stage of your life (P8). 
 
 P1 said that he has made short-term PrEP prescriptions for about a quarter of his patients. 
In addition to the reasons stated by P8, P1 added that his patients who seek PrEP because they are 
in serodiscordant relationships typically stop taking PrEP when those relationships end. It should 
be noted that this list of reasons for taking episodic PrEP is not intended to be exhaustive, and 
there may be other reasons that were not identified by participants. 
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4.4 PREP NEEDS, ACCESS AND PERCEPTIONS DIFFER BY RACE AND AGE 
AMONG MSM. 
While participants identified unique characteristics of several subpopulations of MSM, differences 
by age and race were consistently discussed across the interviews. Specific characteristics about 
needs, access, and perceptions of PrEP were discussed in particular. 
 Several participants articulated that focusing efforts on Black MSM and transwomen is 
important because of their simultaneous higher risk for HIV infection and less engagement with 
medical care. P9 made a point that expands on this: 
I think if you're black, there are barriers to accessing healthcare, period. If you're 
a black gay man, the places you can go and be treated with respect are limited. 
You're less likely, just demographically, to have insurance or good insurance. If 
you're not out publicly and feel comfortable and empowered around your sexuality, 
the likelihood that you're going to say, "I'm going to get PrEP," is probably pretty 
low. Again, I think there's a stigma that sometimes in the African American 
community can be stronger around religious prohibition about that kind of stuff 
(P9). 
 
 P8 described unique attitudes about PrEP among his clients, who are primarily young Black 
MSM and see PrEP as “needed for survival” because of the disparity of HIV by race among MSM. 
He expanded on his point that the stigma of PrEP as a “party drug” is unique to “middle-aged, 
work-force men” (see table 2) and said:  
I think that especially in the African-American community, the chances [of HIV 
infection] are really high. Like, even if I have sex for the first time, or if I've only 
ever had five sexual partners, nine times out of ten I've come across someone who 
was positive… For a young, black MSM it's not [a joke] (P8). 
 
 Additionally, several participants articulated the importance that health communications 
about PrEP are inclusive of racial minorities. As P2 said, materials that are not inclusive are 
“automatically going to turn people off.”  
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4.5 RISK COMPENSATION IS REAL, BUT IT SHOULD NOT BE USED TO 
PROHIBIT PREP UPTAKE. 
Several participants spoke about risk compensation, and the two medical providers of the sample 
spoke specifically about risk compensation among their patients who are on PrEP. When speaking 
about the stigma of PrEP as a “party drug,” P1 said:  
I don't know that it's going to cause this feeding frenzy of crazy, condomless sex. 
The reality is, people have lots of condomless sex right now, anyway. I suppose, if 
you could somehow prove that PrEP was going to take all the people who are using 
condoms right now, and change their thoughts, then yeah, that would probably 
constitute risk compensation (P1). 
 
 Thus, P1 indicated that many MSM who are on PrEP and not always using condoms were 
very likely not using condoms before going on PrEP, either. He called it “paternalistic” to tell 
someone to not go on PrEP because of possible behaviors that he may or may not take: 
I certainly think that as doctors or medical providers, we don't get to make 
that decision. This seems very paternalistic to say, "No, you can't have something 
that can potentially safe your life, because you might have more sex." (P1). 
 
With that being said, he said that risk compensation does happen: 
[Risk compensation] is real, it's a question of how real will it be? I sometimes like 
to ask people, "So, do you feel like, since starting PrEP, you use [condoms] less 
frequently, or had more condomless sex, or more partners?" A good number of 
people say, "Well, yeah. I don't need to use condoms anymore” (P1). 
 
However, risk compensation’s effects may be mitigated by PrEP’s clinical guidelines, 
which call for comprehensive blood testing every three months, including STI testing: 
If you are engaging them in care and are able to screen them for STIs frequently, 
then you're actually doing a really good thing in terms of at least treating their STIs 
before they go out and spread it to the entire world (P1). 
 
P7 echoed this sentiment in stating: 
PrEP clinics absolutely have to have a very strong role and acknowledgment as 
STI clinics as well (P7). 
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5.0  DISCUSSION 
These discussions aimed to uncover and make explicit barriers to PrEP uptake and ways to mitigate 
these barriers, and in the process some specific attitudes about PrEP emerged. The barriers 
presented in this paper are intended to be extensive but not exhaustive. Table 3 lists all of the 
barriers that emerged in the interviews, and this table may serve as a guide to intervention design. 
These barriers are expanded upon below and are presented from a Social Ecological perspective. 
The importance of any single barrier or construct over another is not assessed, however, some of 
the barriers and constructs had more salience among interview participants.  
The word “stigma” triggered conversation that extended beyond PrEP itself to include 
attitudes about sex and MSM identity more generally. Given that the eligibility criteria for PrEP 
requires an individual to divulge sensitive information about sexual behavior, stigma has formed 
around PrEP that it is only for “slutty” people or only for people who want to use it as a “party 
drug.” Thinking about stigma invokes application of the Theory of Planned Behavior and 
examination of attitudes and subjective norms that emerge when talking about PrEP. While the 
significance of access-related and knowledge-related barriers cannot be overstated, when thinking 
about public health practice the particular salience of stigma-related barriers among interview 
participants calls for pause. For example, MSM who do not have access to PrEP because of 
financial reasons may be assisted by improving payment assistance mechanisms, but MSM who 
do not want PrEP because they are embarrassed or ashamed require interventions that are less 
straightforward. How and where does that conversation begin for someone when PrEP is a 
nonstarter?  
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We need the normative consensus among MSM to shift from that of a “party drug” that 
only “sluts” take to something that health-conscious people do to keep themselves and their 
communities safer. As described by participants in this sample, views of PrEP among the 
community as a “party drug” imply that PrEP’s sole purpose is to enable MSM to have 
condomless sex with multiple partners because it significantly reduces fear of HIV infection. The 
term “Truvada whore” emerged in the interviews as a derogatory label ascribed to MSM who use 
PrEP, a label that pulls from assumptions about sexual promiscuity. A shift in the normative 
consensus about PrEP represents an empowerment perspective, because it turns PrEP from a signal 
of sexual promiscuity (which interview participants agreed is stigmatized) to a signal of 
responsibility and proactive self-care. Building upon attitudes and normative beliefs about PrEP 
that are positive and empowering may assuage the stigma associated with PrEP uptake and use.  
These normative beliefs among MSM may arise from what the literature refers to as “risk 
compensation.” Risk compensation in the context of these interviews and the literature on PrEP 
describes how individuals may stop or decrease other HIV protective behavior after going on PrEP, 
compensating one risk for another. HIV protective behavior besides PrEP use may include condom 
use and number of sexual partners. Informants in this sample said that risk compensation is a reality 
and important for healthcare providers to talk with their patients about, however, consensus was 
that the possibility of risk compensation does not warrant prohibiting PrEP among people who 
need it. Participants pointed out that PrEP is a harm reduction approach, and it may be a viable 
prevention option for people who are not using condoms in the first place. With that being said, 
PrEP is FDA-approved as a combination prevention method to be used in conjunction with 
condoms, and it should not supplant condoms.  
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Another important point that emerged in the interviews is that the clinical guidelines for 
PrEP may mitigate the effects of risk compensation. PrEP requires ongoing engagement with 
healthcare for those who have a prescription. This is especially important in light of findings from 
research using the Theory of Syndemic Production that find that high-risk MSM may be less likely 
to engage in health services. To maintain a PrEP prescription an individual must visit their provider 
for comprehensive blood testing every three months, including STI testing. In the experience of 
P1, STIs are being detected and treated sooner among his patients who are on PrEP. Thus, as PrEP 
use increases it is imperative that providers are educated about these guidelines for ongoing PrEP 
prescriptions.  
In viewing PrEP through the lens of harm reduction, PrEP may be seen as an important 
HIV prevention method that meets people where they are. As P11 said on PrEP and harm 
reduction, PrEP “keep[s] people as healthy as we can until they get to the place where they want 
to be.” This brings to mind the Transtheoretical Model (TTM) and its stages of health behavior 
change. As found in the literature and these interviews, MSM who never use condoms during sex 
may deem PrEP to be an acceptable form of HIV prevention. Thus, interventions to increase HIV 
protective behavior among this population should assess stages of change indicators for both 
condom use and PrEP use. For example, an individual may be in the precontemplation stage for 
condom use but in the preparation stage for PrEP use, or vice versa. Since PrEP needs to be used 
in conjunction with condoms, it is important for PrEP interventions to include condom use. 
Interventions may do this by applying the TTM to move individuals through the stages of change 
for both behaviors as long as they are needed. 
The Health Belief Model (HBM) may also inform interventions that aim to increase PrEP 
uptake. Some barriers related to access and knowledge/attitudes in Table 3 are the cost of PrEP, 
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fear of side effects, and inaccurate self-assessment of HIV risk among MSM. These are textbook 
examples of the HBM constructs of perceived barriers to change, perceived costs of a behavior, 
and perceived susceptibility to illness. If an individual’s perceived barriers/costs are high, and/or 
his perceived susceptibility to HIV is low, the HBM predicts that he will not seek HIV protective 
behavior. Furthermore, the discussion of “fatalistic attitudes” in these interviews may call for 
measures of self-efficacy, another construct of the HBM. As P5 indicated, if an individual believes 
that “[he] is going to get [HIV] anyway” and cannot avoid it, then it may be difficult to engage 
him in HIV protective behavior in general. 
Access-related barriers also need to be addressed in intervention design. Some of these 
barriers identified in this sample are common in the literature, including cost and insurance issues, 
but some are not so common. Of particular contribution may be the access-related barrier of 
insufficient capacity among organizations, because PrEP’s clinical guidelines require considerable 
resources of personnel, time, space, connections to laboratories, equipment, and financial costs 
associated with these.    
Barriers to PrEP described in this sample occur at multiple levels and thus, Social 
Ecological (SE) perspectives to intervention design are necessary. As discussed in this section, 
individual decision-making about PrEP use may be influenced at the community level by 
reframing PrEP as a positive health behavior, and education of the community and providers alike; 
at the interpersonal level through accurate conversations between providers and patients about 
actual HIV risk, HIV prevention needs, and the PrEP treatment regimen; and at the individual level 
by addressing “fatalistic attitudes” about HIV risk. At the structural level, PrEP uptake may be 
facilitated by continued payment assistance mechanisms, expanding Medicaid coverage 
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nationally, programs that cover pre-prescription laboratory testing, advocating for FDA-approval 
of episodic PrEP, and organizational capacity building. 
5.1 USING THESE FINDINGS FOR INTERVENTION DESIGN 
Healthcare navigators and specifically PrEP navigators who serve to answer community inquiries 
about PrEP may be particularly helpful. As P1 said, his clinic receives phone calls from the 
community with questions about PrEP, but due to policy constraints, he cannot answer questions 
from anyone who has not been seen by the clinic. A PrEP navigator may be employed by a local 
health department or a prominent local nonprofit and may serve as the go-to community resource 
for all things PrEP. PrEP navigators should have a strong working knowledge about PrEP’s 
eligibility criteria, the breadth of payment assistance options, and the research literature about 
PrEP; relationships with local providers who are known for fluency in issues related to PrEP, 
sexual health, and sexual minorities; and a demonstrated ability to communicate scientific health 
information to lay audiences effectively.  
Health communication campaigns that educate the community and reframe PrEP as 
positive and empowering may also be helpful. Communications should use multiple channels and 
include messaging that is informative, nonjudgmental, and inclusive of racial minorities. Key 
information should include PrEP’s eligibility criteria, where to get a prescription, payment 
assistance options, and resources to learn more. Qualitative research may fine-tune any 
communications product (e.g., posters, social media posts, videos) to greater resonate with the 
target audience. Given the disparity of HIV experienced by Black MSM, and the lack of focus on 
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Black MSM in existing PrEP expansion efforts that was identified in these interviews, messaging 
that targets this community is particularly needed. 
 Advocating for the FDA-approval of episodic PrEP may be useful, as well. Episodic PrEP 
may increase PrEP uptake by decreasing costs and promoting adherence. Costs may be decreased 
because participants in the treatment arm of the IPERGAY trial took a median of 14 tablets per 
month (40), half of what is needed for a daily regimen. Furthermore, daily adherence is a sizable 
issue. Forty-five percent of the participants in the original iPrEx trial, who were instructed to take 
the pill every day, did not have any traces of the drug in their blood (13). Findings from these 
interviews are congruent with the claim that episodic PrEP may increase PrEP uptake, because 
participants agreed that episodic PrEP is viewed favorably among MSM that they work with. 
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6.0  CONCLUSION 
The iPrEx and IPERGAY trials demonstrated PrEP’s efficacy among MSM, and subsequent work 
found evidence of its acceptability among high-risk MSM. However, many MSM who could 
benefit from PrEP are not connected to it. Expanding PrEP access, along with expanding access to 
testing services and antiretroviral treatment, is a key tenet to ending the HIV/AIDS epidemic. 
Barriers to PrEP uptake need to be articulated and examined if we are to identify intervention 
designs and increase PrEP uptake and use. It is with this in mind that I conducted interviews and 
consolidated my findings with conceptual frameworks and the extant literature to provide 
recommendations to bolster PrEP uptake among MSM in the United States. It should be noted that 
these findings represent barriers to PrEP uptake as identified by interview participants in this 
sample, and qualitative research in other settings may elicit different or additional findings. 
PrEP is gaining momentum among public health officials and HIV prevention 
professionals nationwide. Large-scale clinical trials have demonstrated its efficacy, and HIV/AIDS 
campaigns at the federal, state, and local levels have identified expanding PrEP access as integral 
to ending the epidemic. Practitioners, advocates and policymakers should harness this momentum 
for fighting the epidemic in innovative ways. 
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6.1 SUMMARY 
This study adds to the discussion about PrEP uptake among MSM. First, an overview is presented 
that described PrEP’s context, its efficacy, and current research findings about barriers and 
facilitators to PrEP uptake. Then, this study’s methods are described in detail, followed by the 
presentation of primary qualitative data that was gathered during individual and group interview 
sessions with experts in HIV/AIDS research and practice, from February-March 2016, in 
Pittsburgh, Pennsylvania. The discussion that follows consolidated these data with conceptual 
frameworks to enlighten or guide practitioners, researchers, and policymakers who seek to enhance 
PrEP uptake among MSM. While determining absolute importance of any barrier over another is 
not the goal of this paper, the particular salience of stigma-related barriers among participants was 
not expected, and the implications of this are discussed. Three specific intervention approaches are 
identified that target multiple barriers to PrEP uptake that emerged in this study. 
6.2 LIMITATIONS 
One limitation of this study is the sample is relatively small. Interview participants were 
purposively sampled because of their employment with HIV-related organizations and their 
openness to working with MSM populations. All participants live and work in Pittsburgh, 
Pennsylvania, and their experiences may not be generalizable to areas of vastly different 
demographics, HIV prevalence, population size, or other important environmental variables. 
However, this study has several strengths. As a qualitative study it serves an exploratory purpose 
and generalizability is not necessarily the goal of this research. A group of experts were sampled 
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who have diverse educational backgrounds, and they represent varying disciplines and roles from 
multiple levels of organizations across multiple sectors. Study findings and conclusions are further 
strengthened by the assumption that interview participants have expansive knowledge about the 
communities that they work with.  
6.3 PUBLIC HEALTH SIGNIFICANCE 
The complicated stigma that has formed around PrEP use needs to be deconstructed. Views of 
PrEP that reduce it to a “party drug” minimize its innovative contribution to HIV prevention to 
the detriment of the community. Its ability to empower individuals to take care of themselves and 
their sexual partners in a new way should not be overlooked. Quantitative research in US-based 
samples that tests the relationship of PrEP use and STI incidence may enlighten the controversy 
associated with PrEP use and risk compensation. Given that PrEP is a relatively new prevention 
method, continued research is needed to better understand any other unintended consequences of 
PrEP should they arise in the near or distant future. 
 Stigma-related barriers were highly salient among interview participants, but public health 
practitioners who aim to increase PrEP uptake should target multiple barriers across constructs for 
maximum effectiveness. While stigma emerged as more significant for practice than expected, 
barriers related to access and knowledge/attitudes must be addressed. In this way, Table 3 may 
serve as a map to intervention design. Local practitioners should create PrEP enhancement efforts 
that are informed by a strong knowledge of the needs, attitudes, and knowledge of PrEP within 
their specific community, and further qualitative research can help with that. In general, PrEP 
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navigators and health communication campaigns are two approaches that may be particularly 
effective, and episodic PrEP may simultaneously diminish costs and promote adherence. 
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APPENDIX A: RECRUITMENT EMAIL 
Dear [NAME], 
You are invited to participate in a research study that I am conducting. I am a Master of 
Public Health student in Pitt Public Health’s Center for LGBT Health Research and a Master of 
Public Administration student in Pitt's Graduate School of Public and International Affairs. This 
study aims to understand barriers to PrEP use among men who have sex with men, with a focus 
on the Pittsburgh region. I hope to interview local experts in the field as a component of this 
project. 
Would you be willing to meet with me for a 30- to 60-minute interview in the next 
two to three weeks? Your expertise as [PARTICIPANT JOB TITLE] is valuable because I am 
exploring how HIV-focused nonprofits and clinics are utilizing (or not utilizing) PrEP. This 
interview will be about [ORGANIZATION NAME], and the community you work with, not 
about you individually.  
If you choose to participate, please let me know as soon as possible. You can send me the 
dates and times that you are available, and the place you would prefer to meet. I would like to 
record the interview, so a quiet location would be ideal. I can travel to your workplace for the 
interview if that is most convenient. Thank you for your time, and I look forward to hearing from 
you. 
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APPENDIX B: INTERVIEW GUIDE 
Introduction and consent script: 
Thank you for taking the time to sit down with me and talk about your thoughts and 
experiences with HIV pre-exposure prophylaxis in the work that you do. Your input will be 
valuable in composing my Masters’ thesis and finding ways to better connect MSM in Pittsburgh 
to PrEP. 
While PrEP can be used in several populations, I am interested in MSM for this project. 
I’ve decided to focus on Pittsburgh because this is a mid-sized city that is a hub of HIV/AIDS 
research and practice, and there are a number of experts locally, such as yourself, whose insight 
may be helpful for other regions too. I am aiming to interview a representative group of 
organizations that work in HIV to get a “big-picture” view.  
My questions today will mostly focus on [PARTICIPANT’S ORGANIZATION NAME] 
and your role within it. Next, I will ask questions about barriers to PrEP uptake. Lastly, I will ask 
about how barriers might be mitigated. I’ve typed up some questions ahead of time, but they will 
serve as a guide more than a hard script. Some of the questions may seem obvious, but this 
interview is about your experiences and knowledge, and I do not want to impose mine. 
Your participation is voluntary, and you may decline to answer any question, for any 
reason. You may stop the interview at any time if you choose not to continue. Please let me know 
at any time during the interview if you have any questions or would like me to explain what I mean 
by any of the terms being used or questions being asked.  
As you know, I am recording this interview. The recordings will be transcribed and I will 
analyze them to write my report. I will not use the recording for any other purpose. Any personally 
identifying information about you will remain confidential, and I will not use your name or 
personally identifying information in any reports. The name of your organization may be included. 
Do you have any questions?  
Let’s begin.  
 
1. Organization 
a. Tell me about your educational background. How long have you been working in HIV? 
b. Tell me about [organization name].  
i. What is its structure?  
1. How much staff and of what types? 
ii. How are decisions made in [organization name]?  
1. Is there a mission statement? 
iii. What is the organizational culture like?  
iv. How did the clinic start? How long has it been around? 
c. Tell me about your role in this organization. 
d. Tell me about the community you see here. 
i. What are their demographics? Are they mostly homogenous in terms of race, 
education, age, and income, or are they diverse? How many are positive and 
negative? 
e. How much is PrEP a part of this organization’s operations? 
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i. Do you do HIV testing? How many people does your agency test? What kind of 
tests do you provide? What population(s) get tested here?  
 
2. Barriers: stigma, cost, and knowledge 
a. Why might a man who has sex with men in Pittsburgh not be on PrEP? 
i. Differences by race? By age? 
b. What are some PrEP access issues in the community you work with?  
i. Do people know about PrEP? 
ii. Do people know where and how to get PrEP? 
iii. How many people that come here are insured? Medicaid or private insurance? 
Uninsured? 
iv. Has anyone used payment assistance programs for PrEP? Do people who 
come here for services know about them? 
c. What have you heard about stigma and PrEP in the community you work with?  
i. Risk compensation fears  
ii. Signaling as sexually promiscuous 
iii. Mixed messages from HIV prevention field 
iv. What might you tell a client who meets the criteria for PrEP but voices these 
concerns? 
d. How do your patients/clients get connected to your organization? 
i. Do they bring up PrEP, or do you/your providers?  
e. What are some concerns about taking PrEP that you hear from the patients/clients you 
work with?  
 
3. Mitigating barriers: education, outreach, programs, policies 
a. What might governmental organizations do to help your patients be connected to PrEP? 
How about nonprofits? Private-sector organizations? 
b. What does your agency do to increase PrEP knowledge among patients who are eligible? 
Or among the community at large? 
c. How is PrEP different for Black MSM, compared to white MSM? Are there differences 
in stigma or access? What approaches and practices are needed? 
d. How did your organizational policies change when you started working with PrEP? If 
they haven’t changed, are there ways that you would like them to change? 
i. Continuing education support for providers 
ii. Train and educate front-line staff 
iii. PrEP champion 
iv. Protocol to accommodate testing every 3 months 
 
4. Miscellaneous 
a. What unintended consequences have you noticed PrEP having in your patients? 
b. What do you hope your organization can do with PrEP that it is not already? 
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